| HOME >> MEDICINE >> TECHNOLOGY |
SVNT-I
(Tables to Follow)SAVIENT PHARMACEUTICALS, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(In thousands, except share data)December 31, 2010December 31, 2009ASSETSCurrent Assets:Cash and cash equivalents$
44,791$
108,172Short-term investments20,0703Accounts receivable, net909352Inventories, net3,140585Recoverable income taxes—2,006Prepaid expenses and other current assets2,4151,402Total current assets71,325112,520Deferred income taxes, net4,2004,200Property and equipment, net809993Other assets (including restricted cash)1,2841,295Total assets$
77,618$
119,008LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable$
1,601$
7,915Deferred revenues42873Warrant liability—24,239Other current liabilities16,02312,473Total current liabilities18,05244,700Other liabilities10,29910,109Commitments and contingenciesStockholders' Equity:Preferred stock—$.01 par value 4,000,000 shares authorized; no shares issued——Common stock—$.01 par value 150,000,000 shares authorized; 70,259,000 issued and outstanding at December 31, 2010 and 66,933,000 shares issued and outstanding at December 31, 2009703669Additional paid-in-capital364,139305,994Accumulated deficit(315,576)(242,467)Accumulated other comprehensive income13Total stockholders' equity49,26764,199Total liabilities and stockholders' equity$
77,618$
119,008SAVIENT PHARMACEUTICALS, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share data)Three Months Ended
December 31,Year Ended
December 31,2010200920102009Revenues:Product sales, net$
960$
864$
4,028$
2,956Other revenues
'/>"/>
| SOURCE Savient Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved |